Navigation Links
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
Date:12/29/2008

dicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic tools, which is unproven and may never lead to commercially accepted products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop and commercialize its candidate tools, products and services; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Contact: Media & Investors, Ron Kamienchick, T: +1-(646)-509-1893, E:

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
2. Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
3. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
4. /C O R R E C T I O N -- Rosetta Genomics Ltd/
5. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference
6. Rosetta Genomics to Present at Oppenheimers 19th Annual Healthcare Conference
7. Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
8. Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative
9. Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer"
10. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
11. Rosetta Genomics Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 One of the major revolutions taking ... which is the practice of using genomic and other ... individual biology. Personalized diagnostics—laboratory analyses that inform the practice ... lab,s future. This fall, AACC ,s first ever ... in this exciting field and the novel technologies driving ...
(Date:8/1/2014)... August 1, 2014 According to ... "Biophotonics Market - Global Industry Analysis, Size, Share, Growth, ... valued at USD 25.16 billion in 2013, which is ... at a CAGR of 10.4% from 2014 to 2020. ... http://www.transparencymarketresearch.com/biophotonics-market.html Increasing demand for accurate early ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Once a ... it cost? This webinar will discuss how to define ... , Join speakers Bob Allen, Senior Director of Facilities ... Process Engineering at Fluor Industrial Services, and special guest ... Asset Planning at Amgen, as they provide an examination ...
(Date:8/1/2014)... Cambrex Corporation (NYSE: CBM ) reports results for ... Highlights , Second quarter sales increased 59% to ... year. , Second quarter EBITDA increased 86% to $21.2 ... year (see table at the end of this release). ... of foreign currency, to between 13% and 16% over 2013, ...
Breaking Biology Technology:First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16
... importance on ... indication-specific FDA approval, WALTHAM, Mass., April 2, 2008 ... into the marketing of biliary,stents for off-label uses in the ... could become a key focus for,stent manufacturers. A recent study ...
... 25 Global Pharmaceutical Companies Select Drug ... MOUNTAIN VIEW, Calif., April 2, 2008 ,Pharsight ... of software,strategic consulting, and regulatory services for optimizing ... global pharmaceutical,companies have become customers for its Drug ...
... Nutritional Distributor in Greece, to Purchase an Aggregate ... of Over $200,000 of Resurgex(R) in 2008, ... a wholly owned subsidiary of Millennium,Biotechnologies Group, Inc. (OTC Bulletin ... purchase order for the international,distribution of the Resurgex(R) line in ...
Cached Biology Technology:Off-Label Stent Use: How Important Are FDA Approvals to Physicians? 2Pharsight Signs Two New DMX(R) License Customers 2Pharsight Signs Two New DMX(R) License Customers 3Millennium Announces $200,000 Purchase Order From Greek Distributor 2Millennium Announces $200,000 Purchase Order From Greek Distributor 3
(Date:7/31/2014)... Researchers who studied 100 twin pairs have identified a ... on less than six hours of sleep per night. ... the effects of sleep deprivation. , Results show that a ... had an average nightly sleep duration of only five ... non-carrier twin, who slept for about six hours and five ...
(Date:7/31/2014)... in German . ... similar to a sponge that soaks up liquids. Hence, ... or greenhouse gases. However, loading of many MOFs is ... (KIT) now report in Nature Communications that ... surface. This can be prevented by water-free synthesis and ...
(Date:7/31/2014)... has been made to help better identify and treat those ... narrowing and enlarging of medium sized arteries in the body, ... organs causing damage. In a new report appearing in August ... scientists provide evidence that that FMD may not be limited ... a connection to abnormalities of bones and joints, as well ...
Breaking Biology News(10 mins):Study of twins discovers gene mutation linked to short sleep duration 2Free pores for molecule transport 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... Scientists at the University of Idaho currently are involved ... been running rampant for the past decade. But the killer,s ... Instead, it,s on the minds of ecologists on every continent ... (Bd). It is a "chytrid" fungus that lives on ...
... to slam the Gulf Coast, and even reason to believe ... How we handle them will be the primary topic of ... Global Climate Impact in the Gulf Coast Conference Oct. 29-31. ... and Evacuation from Disaster Center, primary sponsor of the conference. ...
... 2008Three years after Hurricane Katrina devastated New Orleans, people ... city,s floodwall system. A new article in the fall ... 3) suggests that Formosan subterranean termites played a large ... Louisiana State University AgCenter, discovered Formosan subterranean termites (Coptotermes ...
Cached Biology News:Modern genetics vs. ancient frog-killing fungus 2Modern genetics vs. ancient frog-killing fungus 3Weather woes emphasize need for SSPEED 2Did termites help Katrina destroy New Orleans floodwalls? 2
AVOID FREEZE/THAW CYCLES. Recognizes the ~32 kDa DNase IIα chain and the ~40 kDa proenzyme. DNase II causes both DNA condensation and DNA fragmentation. ...
BD BioCoat Vented Caps for 175 cm2 Flasks...
...
I-Ab MHC Class II...
Biology Products: